Nimbus Announces Change to Business Board
News Nov 22, 2005
Nimbus Biotechnology has reported a change to the company’s Supervisory Board. Professor Axel Kleemann, formerly executive board member of Asta Medica AG has been appointed as a new member and chairman of the Supervisory Board.
Professor Thomas Bayerl, Dr. Rainer Strohmenger (Wellington Partners Venture Capital GmbH, Germany), Jack Griffin and Mario Ober (CFH, Germany) continue to be board members.
Nimbus Biotechnology thanks Werner Zollner (Seed GmbH, Germany) for his former work and support in this position.
Wolfgang Lerch, CEO of Nimbus Biotechnology, stated, "The appointment of Professor Axel Kleemann is a very special opportunity for Nimbus Biotechnology."
"With his expertise we will strengthen our mission to support our customers with cutting-edge tools."
"We will come closer to developing modern tools for all stages of drug discovery. All employees of the company wish him success for his work."
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Chili Pepper Derived Anti-Obesity Drug Shows Promise in Animal TrialsNews
A novel drug based on capsaicin, the compound that gives chili peppers their spicy burn, caused long term weight loss and improved metabolic health in mice eating a high fat diet.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019